Cell and Gene Therapy Catapult opens new Process Analytical Technologies laboratory

March 14, 2023
Business Services

London, 14 March 2023: The Cell and Gene Therapy Catapult (CGT Catapult) today announces the opening of a new laboratory …

US bill pushes Medicare and Medicaid categories for prescription digital therapeutics

March 14, 2023
Medical Communications

Both the US House of Representatives and Senate are considering a bill which would encourage the adoption of prescription digital …

GSK shares positive results from meningococcal disease vaccine trial

March 14, 2023
Research and Development

GSK has announced positive results from its vaccine candidate trial for meningococcal, which is a significant cause of meningitis and …

Occlutech launches FROST-HF study of heart failure device

March 14, 2023
Research and Development

Occlutech has announced that it has recruited its first patient in the FROST-HF study, which aims to investigate the company’s …

Pfizer signs $43bn deal to buy Seagen

March 14, 2023
Sales and Marketing

Pharma giant Pfizer has signed a definitive merger agreement valued at $43bn to buy biotech firm Seagen.   US-based Seagen …

Scottish patients with the most aggressive form of viral hepatitis become first in UK to be offered routine NHS access to Hepcludex® (bulevirtide)

March 14, 2023
Business Services

Monday 13 March 2023, London, UK – Gilead Sciences Ltd today announced that the Scottish Medicines Consortium (SMC) has become …

Cingulate and Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate CTx-1301

March 13, 2023
Business Services

KANSAS CITY, KANSAS and PRINCETON, NEW JERSEY – March 13, 2023 – Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing …

Calliditas Announces Primary Endpoint Successfully Met in Phase 3 NefIgArd Trial Evaluating Nefecon® in IgA Nephropathy

March 13, 2023
Business Services

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced positive topline results from the global, randomized, double-blind, placebo-controlled …

Richard Stedman rejoins ACG as the CEO of Engineering Division

March 13, 2023
Business Services

ACG, a leading supplier of integrated manufacturing solutions to the global pharmaceutical and nutraceutical industries, is pleased to announce that …

Sanofi to acquire Provention Bio in $2.9bn deal

March 13, 2023
Sales and Marketing

Sanofi has agreed to acquire Provention Bio as part of a $2.9bn deal that aims to improve the company’s portfolio …

Gilead Sciences wins $175m in ongoing HIV fraud case

March 13, 2023
Sales and Marketing

Gilead Sciences, a research-based biopharmaceutical company, has won again in the lawsuit levelled against clinics, prescribers, medical labs and pharmacies …

Nasal spray that relieves migraines in minutes approved by FDA

March 13, 2023
Medical Communications

Pfizer is planning to launch a fast-acting nasal spray that can relieve pain from migraines in as little as 15 …

Horizon Therapeutics announces real-world treatment results for Dysthyroid Optic Neuropathy drug

March 13, 2023
Medical Communications

Biopharma company Horizon Therapeutics has announced real-world treatment results for its Thyroid Eye Disease (TED) drug in patients with Dysthyroid …

Biotech centre focusing on gene therapies opens in Bristol, UK

March 10, 2023
Medical Communications

A new state-of-the-art facility named the Clinical Biotechnology Centre (CBC) is opening in Bristol, UK. It cost approximately £10m to …

FDA makes unusual ‘misinformation’ comment on Lucira’s EUA for COVID-19 and flu test

March 10, 2023
Sales and Marketing

The FDA has made a rare comment about what happened at Lucira Health’s Emergency Use Authorization (EUA) filing for its …

Acadia Pharmaceuticals awaits FDA decision for first-of-its-kind Rett syndrome drug

March 10, 2023
Research and Development

Acadia Pharmaceuticals is aiming to follow in the footsteps of Reata Pharmaceuticals, who won approval for its novel drug to …

FDA committee supports Roche’s lymphoma treatment

March 10, 2023
Medical Communications

 A committee at the FDA have voted in favour of Roche’s Polivy antibody drug targeting untreated diffuse large B cell …

FlyPharma Europe, Vienna: 2023 conference officially launched

March 9, 2023
Business Services

FlyPharma Europe, Vienna: 2023 conference officially launched   FlyPharma Conferences is pleased to announce its seventh event in Europe, which …

MSD presents Phase 3 data for its Investigational Activin Signaling Inhibitor, in Adults with Pulmonary Arterial Hypertension on Background Therapy

March 9, 2023
Business Services

LONDON, UK, March 6, 2023 – MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA (NYSE: MRK)) today announced …

The Gateway to Local Adoption Series

Latest content